| Patient | Judy Garland |
|---|---|
| Date of birth | 1922-06-10 |
| Identifiers | MRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127 |
| Document date | 1955-07-20 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Four-week review, eleven days after the supervised change to phenobarbital. [S]
Ms. Garland returns eleven days after a four-day admission to the addiction medicine service. Secobarbital was stopped on admission and phenobarbital was started and adjusted with withdrawal scoring; she had a mild tremor and poor sleep on the second night, no seizure and no confusion, and she was discharged on phenobarbital 32.4 mg three times daily. She has taken it as prescribed from the one-week supply and has taken no secobarbital. She was drowsy for the first three days at home, and that has passed. She sleeps four to five hours a night; her sleep diary shows that she lies awake for an hour after late rehearsals. She has kept to one 10 mg dextroamphetamine tablet each morning. She has taken sertraline 50 mg daily without side effects. Her mood is a little better. The dietitian could not see her yet because of a waiting list. [S]
| Element | Detail |
|---|---|
| Admission | Four days; mild tremor on one night; no seizure or delirium |
| Phenobarbital | 32.4 mg three times daily since discharge |
| Secobarbital | None since admission |
| Sleep | Four to five hours; Insomnia Severity Index 18 |
| Dextroamphetamine | 10 mg each morning |
| Mood | PHQ-9 12; GAD-7 11 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Drowsiness after discharge has passed; no fever |
| Neurological | Negative | No tremor, unsteadiness or seizure-like episodes since discharge |
| Psychiatric | Positive | Mood low at times, better than at intake; no thoughts of suicide or self-harm |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 1955-06-22 to 1955-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 1955-06-22 to 1955-07-20 | completed | S |
| Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stop | One tablet each morning for two weeks, then stop | Oral route | 1955-07-20 to 1955-08-03 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-22 to 1955-06-29 | completed | S |
| Sertraline 50 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1955-06-29 | active | S |
| Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbital | One tablet three times daily | Oral route | 1955-07-06 to 1955-07-20 | completed | S |
| Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time | Per the written taper schedule, in two or three divided doses | Oral route | 1955-07-20 | active | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 1955-06-22 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1955-07-20 | Body height | 151 | cm | S |
| 1955-07-20 | Body weight | 47.6 | kg | S |
| 1955-07-20 | Body mass index (BMI) [Ratio] | 20.9 | kg/m2 | S |
| 1955-07-20 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1955-07-20 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1955-07-20 | Heart rate | 82 | /min | S |
| 1955-07-20 | Respiratory rate | 14 | /min | S |
| 1955-07-20 | Body temperature | 36.6 | Cel | S |
| 1955-07-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1955-07-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 1955-07-20 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 11 | {score} | S |
Vital signs recorded on 1955-07-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 118/76, pulse 82; weight 47.6 kg |
| Neurological | No tremor or nystagmus; finger-to-nose and gait normal |
| Psychiatric | Engaged; no signs of sedation or withdrawal |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | Phenobarbital 97.2 mg a day since discharge; no secobarbital; no withdrawal or sedation |
| Referral | Setting for barbiturate withdrawal | Before any reduction | Completed today | Four-day supervised admission completed without a seizure or delirium |
| Medication safety | Taper pace | Reductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performance | Completed today | First step today, 97.2 to 81 mg a day (17%) |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only the hospital's and this clinic's prescriptions |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Completed today | Barbiturates and amphetamine, as prescribed; nothing else |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Two-week supply from today; locked box |
| Medication safety | Stimulant dose, extra doses, cravings, and blood pressure and pulse | Every visit | Completed today | 10 mg each morning, no extra doses; blood pressure 118/76, pulse 82; taper to 5 mg started |
| Examination | Electrocardiogram | Before continuing a stimulant | Up to date | Normal at intake |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | Two CBT-I sessions; Insomnia Severity Index 18 |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 12, item 9 scored 0 |
| Survey | Anxiety (GAD-7) | With each PHQ-9 while anxiety is treated | Completed today | GAD-7 11 |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 50 mg daily for three weeks; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; safety plan reviewed; the 988 Suicide & Crisis Lifeline in her phone |
| Self-management | Psychotherapy | Weekly | Completed today | Weekly sessions continuing |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 47.6 kg, up 1.1 kg; two meals a day |
| Referral | Dietitian visit | Within a month of intake | Deferred | Not yet seen four weeks after intake because of a waiting list. No harm so far: weight is rising and she is eating more. Corrective action: the clinic booked a second dietitian with an earlier opening |
| Medication safety | Contraception that phenobarbital does not weaken | Medroxyprogesterone every 13 weeks | Up to date | First injection at intake; next due in about nine weeks |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used |
| Self-management | Work schedule and driving safety | With each dose change | Completed today | No driving while drowsy; taper steps planned for weeks without major performances |
Goal progress:
Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); Prescription Drug Monitoring Programs (PDMPs) (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)
Follow-up: Nurse phone check before each taper step. Ten-week review in six weeks. Weekly psychotherapy and CBT-I. Next scheduled visit 1955-08-31: ten-week review: phenobarbital taper, life after stopping the stimulant, sleep, mood, weight and work. [S]